

Libya

Tuberculosis profile

Population 2016

6.3 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.61 (0.35–0.95)	9.8 (5.6–15)
Mortality (HIV+TB only)	0.025 (0.015–0.038)	0.4 (0.24–0.6)
Incidence (includes HIV+TB)	2.5 (1.6–3.7)	40 (25–58)
Incidence (HIV+TB only)	0.056 (0.034–0.082)	0.88 (0.55–1.3)
Incidence (MDR/RR-TB)**	0.12 (0.04–0.2)	1.9 (0.63–3.2)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.13 (0.077–0.19)	0.91 (0.53–1.3)	1 (0.61–1.5)
Males	0.15 (0.087–0.21)	1.3 (0.78–1.9)	1.5 (0.87–2.1)
Total	0.28 (0.16–0.39)	2.2 (1.3–3.2)	2.5 (1.6–3.7)

TB case notifications, 2016

Total cases notified	1 176
Total new and relapse	1 131
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	63%
- % bacteriologically confirmed among pulmonary	71%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	45% (31–71)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.27 (0.12–0.44)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	25	2%
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			38 (19–57)
Estimated % of TB cases with MDR/RR-TB	4.1% (1.4–6.9)	16% (13–18)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	61%	966
Previously treated cases, excluding relapse, registered in 2015	22%	51
HIV-positive TB cases registered in 2015	29%	49
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2017

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



New and relapse


Retreatment, excluding relapse

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically